The effect of Atomoxetine on Cognitive Function of Multiple Sclerosis
Phase 3
Recruiting
- Conditions
- Multiple Sclerosis.Demyelinating disease of central nervous system, unspecifiedG37.9
- Registration Number
- IRCT20210715051901N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Diagnosis of Multiple Sclerosis based on McDonald's criteria
Age between 18 to 55 years
Testable Measurable Cognitive impairment (MACFIMS) attributed to Multiple Sclerosis
Exclusion Criteria
Continued use of Stimulant
Clinical relapse of Multiple Sclerosis with in 60 days of screening
Changes in the treatment of Multiple Sclerosis within 90 days of screening
Existence of any underlying factor and disease that causes dementia and cognitive impairment
Proof of moderate to severe depression with a Beck's test
Contraindications to the use of Atomoxetine
Confirmation of cognitive impairment related to Multiple Sclerosis with McFimes test
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive Disorder Score in MacFims Questionnaire. Timepoint: Perform MacFims test at the beginning of the study and three months after the start of the study. Method of measurement: MacFims Questionnaire.
- Secondary Outcome Measures
Name Time Method Accompanying depression score. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Beck Questionnaire.